Targeting PI3K/Akt/mTOR signaling in cancer

Camillo Porta, Chiara Paglino, Alessandra Mosca

Research output: Contribution to journalArticle

396 Citations (Scopus)

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

Original languageEnglish
Article numberArticle 64
JournalFrontiers in Oncology
Volume4 APR
DOIs
Publication statusPublished - 2014

Fingerprint

Phosphatidylinositol 3-Kinase
Sirolimus
Neoplasms
Cell Survival
Growth

Keywords

  • Akt
  • Everolimus
  • Inhibitors
  • MTOR
  • Novel agents
  • PI3K
  • Ridaforolimus
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Targeting PI3K/Akt/mTOR signaling in cancer. / Porta, Camillo; Paglino, Chiara; Mosca, Alessandra.

In: Frontiers in Oncology, Vol. 4 APR, Article 64, 2014.

Research output: Contribution to journalArticle

Porta, Camillo ; Paglino, Chiara ; Mosca, Alessandra. / Targeting PI3K/Akt/mTOR signaling in cancer. In: Frontiers in Oncology. 2014 ; Vol. 4 APR.
@article{06cc32a60b1b43d2a12901ad5570e175,
title = "Targeting PI3K/Akt/mTOR signaling in cancer",
abstract = "The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.",
keywords = "Akt, Everolimus, Inhibitors, MTOR, Novel agents, PI3K, Ridaforolimus, Temsirolimus",
author = "Camillo Porta and Chiara Paglino and Alessandra Mosca",
year = "2014",
doi = "10.3389/fonc.2014.00064",
language = "English",
volume = "4 APR",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Targeting PI3K/Akt/mTOR signaling in cancer

AU - Porta, Camillo

AU - Paglino, Chiara

AU - Mosca, Alessandra

PY - 2014

Y1 - 2014

N2 - The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

AB - The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

KW - Akt

KW - Everolimus

KW - Inhibitors

KW - MTOR

KW - Novel agents

KW - PI3K

KW - Ridaforolimus

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84901008792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901008792&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00064

DO - 10.3389/fonc.2014.00064

M3 - Article

VL - 4 APR

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 64

ER -